Certolizumab good choice for RA in Finland
The researchers developed a model to assess the cost effectiveness and budget impact of certolizumab pegol over a 5-year time period, with or without an rSs, at treatment initiation as an alternative option for patients with moderate-to-severe RA, compared with the current treatment mix of reimbursed biologics.· The RSS included a treatment switch and refund of the certolizumab acquisition costs if patients failed to achieve ACR··20 response. "The hypothetical RSS modeled in this study could potentially improve ACR response, QALY, and economic outcomes associated with moderate-to-severe RA in Finland," suggest the researchers. * The study was funded by UCB Pharma Oy Finland. *· American College of Rheumatology Soini E, et al..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
PharmacoEconomics & outcomes news - (2017), 789, Seite 13-13 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1999600525 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1999600525 | ||
| 003 | DE-627 | ||
| 005 | 20230512080541.0 | ||
| 007 | tu | ||
| 008 | 171228s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1999600525 | ||
| 035 | |a (DE-599)GBVOLC1999600525 | ||
| 035 | |a (PRQ)proquest_journals_19737396900 | ||
| 035 | |a (KEY)0248955420170000000078900013certolizumabgoodchoiceforrainfinland | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 245 | 1 | 0 | |a Certolizumab good choice for RA in Finland |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The researchers developed a model to assess the cost effectiveness and budget impact of certolizumab pegol over a 5-year time period, with or without an rSs, at treatment initiation as an alternative option for patients with moderate-to-severe RA, compared with the current treatment mix of reimbursed biologics.· The RSS included a treatment switch and refund of the certolizumab acquisition costs if patients failed to achieve ACR··20 response. "The hypothetical RSS modeled in this study could potentially improve ACR response, QALY, and economic outcomes associated with moderate-to-severe RA in Finland," suggest the researchers. * The study was funded by UCB Pharma Oy Finland. *· American College of Rheumatology Soini E, et al. | ||
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Researchers | |
| 650 | 4 | |a Patients | |
| 650 | 4 | |a Cost control | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d Auckland : Wolters Kluwer Health Adis, 1996 |g (2017), 789, Seite 13-13 |w (DE-627)193388901 |w (DE-600)1308910-9 |w (DE-576)435516213 |x 1173-5503 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:789 |g pages:13-13 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1973739690 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2017 |e 789 |h 13-13 | ||